🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Vascular complications of AF in cancer patients are main clinical challenges, don’t miss this new study and our accompanying editorial!! JACC Journals IEO sciencedirect.com/science/articl…

Very concerning, particularly the rise in PE mortality in younger people with cancer

Sad to see this. Important to know that DVT - commonly perceived to be a complication in older or hospitalized individuals - can affect completely healthy, young people and even athletes. Many more such stories on NBCA

DESTINY-Gastric04 demonstrated significantly prolonged OS with T-DXd vs. PTX+RAM in HER2+ gastric cancer. A major advancement for patients! Congratulations to all involved! OncoAlert OncoDaily Daiichi Sankyo US AstraZeneca daiichisankyo.com/files/news/pre…

Mattehorn study showed EFS improvement and strong OS trend with FLOT+duravalumab. Great news to establish the global standard for fit patients with locally advanced gastric/GEJ cancer. Looking forward to the detail.OncoAlert OncoDaily astrazeneca.com/media-centre/p…

Retrospective analysis of MTB impact on the care of patients with GI tumors at IEO just published in ESMO Open. Among 192 patients discussed at the MTB, 31 (17.7%) were recommended molecularly guided treatment options, experiencing longer rwPFS. esmoopen.com/article/S2059-…

Pivot al paper on CAT! 👏🏻🤩

Just released on JCO Oncology Practice our latest editorial on systemic therapies for advanced #HCC! IEO ascopubs.org/doi/10.1200/OP…

Looking for outstanding Hematology and Medical Oncologists to join our regional HemOnc practices in Ohio and Florida Cleveland Clinic If you are attending ASCO Annual meeting, please visit our booth for more information! Generous benefits and salary Limited J-1 Options

Tough to make improvements even in resectable pancreas cancer. No benefit of neoadj gem/abrax vs mFFX. No comparison to upfront resection so we don't even know of *any* benefit of neoadj therapy at all.

Excellent work by Dr. Tamara Sussman Jean Connors et al confirming high risk of VTE (7-11% 6-12 mo) with immune checkpoint inhibitors in a very large cohort jitc.bmj.com/content/13/5/e…

FLOT/TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative GC/GEJ cancer The Lancet Oncology doi.org/10.1016/S1470-… 🔎 PRODIGE 51-FFCD-GASTFOX phs 3 trial 👉ORR 62 vs 53% 👉mPFS 7·59 vs 5·98 mo 👉mOS 15·08 vs 12·65 mo 🧐Intersting option for fit pts

Now available online our new perspective about clinical challenges of zolbetuximab use in CLDN 18.2-positive gastric cancer! IEO Chiara A. Cella and all coauthors! sciencedirect.com/science/articl…

🔥Plenary Discussion of LBA5🔥 📷 #ASCO2025 👏Great discussion by Sam Klempner 👉D-FLOT reached it's primary endpoint and will change clinical practice 👉More to come: from MATTERHORN to EVEREST ESMO - Eur. Oncology

Announcing the first EVER Journal of Clinical Oncology Art of Oncology Narrative Medicine Contest! 🎉✍️🎗️🩺🎉 We're looking for essays that explore the human experience of cancer and reflect on the experience of trainees and early career hematologists/oncologists. Apply Now! ascopubs.org/jco/art-oncolo…

CLDN18 Expression and Isoform Distribution mainly in GI cancers. Trend of reduced overall CLDN18 expression after chemo with decrease CLDN18.2/18.1 proportion. Need similar analysis of isoform switch after chemo+Zolbe OncoAlert onlinelibrary.wiley.com/doi/10.1111/ca…

A first-in-class EGFR-directed KRAS G12V selective inhibitor Cancer Cell doi.org/10.1016/j.ccel… 👉EFTX-G12V selectively targets KRAS G12V while sparing wild-type KRAS 👉Activity in lung, colon, & PDAC cancer models 🧐 Very interesting MOA, KRAS is becoming draggable ESMO - Eur. Oncology

Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors JAMA Oncology doi.org/10.1001/jamaon… 🔎128 studies, 343 SOTRs 👉Acute rejection: 36.2%; graft loss: 18%, lower risk w/ steroids & mTOR 👉ORR: 31% 🧐ICI my be considered in

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations | Revolution Medicines #ESMOGI25 ir.revmed.com/news-releases/…

Fascinating paper from Chrysaf Jeff Zwicker, MD Avi Leader Rushad Patell et al suggesting nearly half the rate of VTE in individuals with FXI deficiency and cancer - important clinical mplications as FXI targeting agents are being developed for cancer VTE sciencedirect.com/science/articl…